Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Precision financing

Private biotech financing in 2023 is more discriminate, disciplined and demanding. Strong data and efficiency are de rigueur.
  1. Melanie Senior

    1. London, UK.

    View author publications

    You can also search for this author in PubMed  Google Scholar

The 2020s have flung biotech from the heights of pandemic exuberance, when cash grew on trees and anyone with a lab coat could take a company public, to the belt-tightening lows of 2022, with layoffs, liquidations and falling valuations.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Biotechnology 41, 597-603 (2023)

doi: https://doi.org/10.1038/d41587-023-00001-z

Updates & Corrections

  • Update 27 April 2023: A statement in the main text that TargaGenix has shut down has been deleted as it is inaccurate. In addition, two rows were added to Table 1, the first for Orna Therapeutics in 2022 and the second for Chroma Medicine in 2023.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links